No Prescription |
 |
 | ||
|
DUPROST Duagen |
|
| ||
No Prescription » Prescription Drugs 6 » DUPROST Duagen Dutasteride (du-TAS-tur-ide) is used to treat men who have symptoms of an enlarged prostate gland. Dutasteride is used for to treat symptoms of benign prostatic hyperplasia (BPH or enlargement of the prostate gland) and to reduce the risk of urinary blockage and the need for prostate surgery. Treating symptoms of benign prostatic hyperplasia (BPH) or enlargement of the prostate gland. It also helps to reduce the risk of urinary blockage and the need for prostate surgery.Dutasteride is a 5 alpha-reductase enzyme inhibitor. It works by lowering levels of a hormone called dihydrotestosterone (DHT) which is a major cause of prostate growth. Lowering DHT leads to shrinkage of the enlarged prostate gland. Buy DUPROST Duagen and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About DUPROST Duagen: Product Type: Prescription Drugs 6 DUPROST ( Duagen Avodart Generic Dutasteride ) DUPROST (Duagen Avodart Generic Dutasteride) Duagen Avodart Generic Dutasteride 0.5 mg Soft Gel Cap 100 (10 x 10 strips) 200 (20 x 10 strips) Duagen Avodart Generic Dutasteride DUPROST
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
